Week of March 26 - 01, 2017
Take our short survey and help us plan future projects!
Ribociclib is a medication used in combination with another medication, called an aromatase inhibitor. It inhibits cyclin D1/CDK4 and CDK6, which are enzymes that promote cell division and multiplication in cancer cells. This slows the growth of the tumor. These medications are given together because they can keep metastatic cancer from growing for longer periods of time.
First bite syndrome is a side effect of head and neck cancer that causes pain in the mouth when salivating or taking the first bites of food during a meal or snack.
Cervical dystonia is a side effect which causes neck muscles to contract on their own causing abnormal movements and abnormal posture of the head and neck.
Lanreotide is similar to somatostatin, a hormone that occurs naturally in the body. It is used to treat carcinoid syndrome, which can occur in patients with carcinoid or neuroendocrine tumors. These tumors cause the body to overproduce certain hormones, and these hormones in turn can lead to symptoms, such as flushing, racing heart, and diarrhea. The combination of these symptoms are known as “carcinoid syndrome”.
Radiation fibrosis syndrome is a common late side effect of radiation in the treatment of head and neck cancer.
Information about the side effect trismus and how it is treated.
Information about Spinal Accessory Nerve Palsy, a side effect of some treatments for head and neck cancers.
This webinar provides an introduction to the treatment of head and neck cancers, with a focus on radiation therapy and specifically the treatment of head and neck cancers with proton therapy.
Post-transplant lymphoproliferative disorders (PTLD) are a type of lymphoma that are a complication of both solid organ and allogeneic bone marrow or stem cell transplants.
Information about dental care specifically for head and neck cancer survivors.
Provides support and coping information for body image changes during and after head and neck cancer treatment
A look at the role the medical oncology team plays in the interdisciplinary care of head and neck cancer.
A look at the multidisciplinary team in head and neck cancer care and the evaluations needed before treatment can begin.
Rucaparib is a PARP (poly ADP ribose polymerase) inhibitor. Cancers related to BRCA 1 or 2 mutations seem to rely on PARP to repair damaged DNA in cancer cells, allowing them to continue to divide. By inhibiting PARP, tumor growth may be slowed or stopped. A blood test is required prior to starting treatment with rucaparib to determine if you have a BRCA mutation.